| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35234-10ug | |||
| Carrier-Free | NBP2-35234-500ug | |||
| Carrier-Free | NBP2-35234-1000ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-34863-10ug | |||
| Carrier-Free | NBP2-34863-1mg | |||
| Carrier-Free | NBP2-34863-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35136-10ug | |||
| Carrier-Free | NBP2-35136-1mg | |||
| Carrier-Free | NBP2-35136-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75907SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81095-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35020-10ug | |||
| Carrier-Free | NBP2-35020-1mg | |||
| Carrier-Free | NBP2-35020-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35124-10ug | |||
| Carrier-Free | NBP2-35124-1mg | |||
| Carrier-Free | NBP2-35124-500ug | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-75898SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-52693-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-81044-0.025mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Carrier-Free | NBP2-35051-10ug | |||
| Carrier-Free | NBP2-35051-1mg | |||
| Carrier-Free | NBP2-35051-500ug | |||
![Flow Cytometry: F4/80 Antibody (CI:A3-1) [NBP2-61613] - Figure 3 BMDMs were stained with Fc Silent recombinant anti-F4/80 [Cl:A3-1] or isotype control (Fc Silent anti-fluorescein [4-4-20 (enhanced)] IgG2b. These were fluorescently labelled using the secondary antibody, goat IgG anti-rat IgG (H&L-chain) polyclonal antibody directly conjugated to Alexa Fluor 647(AF647) commercially available from a competitor. The Fc silent format however overcomes this issue as seen in Figure 3, where the Fc silent recombinant anti-F4/80 yields a strong and distinct signal, whilst the isotype control shows no discernible difference to the background staining from the secondary antibody alone. Therefore, with Fc Silent reagents, no Fc-blocking products are required. [Data courtesy of Lewis Taylor.]](http://images.novusbio.com/fullsize/F4-80-Antibody-CI-A3-1-Flow-Cytometry-NBP2-61613-img0003.jpg "Flow Cytometry: F4/80 Antibody (CI:A3-1) [NBP2-61613] - Figure 3 BMDMs were stained with Fc Silent recombinant anti-F4/80 [Cl:A3-1] or isotype control (Fc Silent anti-fluorescein [4-4-20 (enhanced)] IgG2b. These were fluorescently labelled using the secondary antibody, goat IgG anti-rat IgG (H&L-chain) polyclonal antibody directly conjugated to Alexa Fluor 647(AF647) commercially available from a competitor. The Fc silent format however overcomes this issue as seen in Figure 3, where the Fc silent recombinant anti-F4/80 yields a strong and distinct signal, whilst the isotype control shows no discernible difference to the background staining from the secondary antibody alone. Therefore, with Fc Silent reagents, no Fc-blocking products are required. [Data courtesy of Lewis Taylor.]")
![SDS-Page: Porcine CXCL8/IL-8 Protein [NBP2-35234]](http://images.novusbio.com/fullsize/Porcine-CXCL8-IL-8-Protein-SDS-Page-NBP2-35234-img0001.jpg "SDS-Page: Porcine CXCL8/IL-8 Protein [NBP2-35234]")
![SDS-Page: Human IL-3 Protein [NBP2-34863]](http://images.novusbio.com/fullsize/Human-IL-3-Protein-SDS-Page-NBP2-34863-img0001.jpg "SDS-Page: Human IL-3 Protein [NBP2-34863]")
![SDS-Page: Mouse IL-7 Protein [NBP2-35136]](http://images.novusbio.com/fullsize/Mouse-IL-7-Protein-SDS-Page-NBP2-35136-img0001.jpg "SDS-Page: Mouse IL-7 Protein [NBP2-35136]")
![Western Blot: CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [NBP2-75907] - Rat spleen (lane 1), rat muscle (lane 2), rat bladder (lane 3), human breast tumour (lane 4) and human thyroid tumour (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with NBP2-75907 at 1 ug/ml before being detected by a secondary antibody. The expected band size (29 kDa) is seen in the human-derived samples, as well as bands corresponding to dimers and other multimers.](http://images.novusbio.com/fullsize/CD40-Ligand-TNFSF5-Antibody-hu5c8-Ruplizumab-Western-Blot-NBP2-75907-img0001.jpg "Western Blot: CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [NBP2-75907] - Rat spleen (lane 1), rat muscle (lane 2), rat bladder (lane 3), human breast tumour (lane 4) and human thyroid tumour (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with NBP2-75907 at 1 ug/ml before being detected by a secondary antibody. The expected band size (29 kDa) is seen in the human-derived samples, as well as bands corresponding to dimers and other multimers.")
![SDS-Page: Human IL-15 Protein [NBP2-35020]](http://images.novusbio.com/fullsize/Human-IL-15-Protein-SDS-Page-NBP2-35020-img0001.jpg "SDS-Page: Human IL-15 Protein [NBP2-35020]")
![SDS-Page: Mouse IL-33 Protein [NBP2-35124]](http://images.novusbio.com/fullsize/Mouse-IL-33-Protein-SDS-Page-NBP2-35124-img0001.jpg "SDS-Page: Mouse IL-33 Protein [NBP2-35124]")
![Western Blot: TNF-alpha Antibody (cA2 (Infliximab)) - Chimeric [NBP2-75898] - Mouse liver (lane 1), mouse spinal cord (lane 2), mouse testis (lane 3), mouse colon (lane 4) and human thyroid tumour (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with NBP2-75898 at 1.5 ug/ml before being detected by a secondary antibody. The expected band size (269 kDa) is seen in the human-derived samples, as well as a band corresponding to dimers.](http://images.novusbio.com/fullsize/TNF-alpha-Antibody-cA2-Infliximab-Chimeric-Western-Blot-NBP2-75898-img0002.jpg "Western Blot: TNF-alpha Antibody (cA2 (Infliximab)) - Chimeric [NBP2-75898] - Mouse liver (lane 1), mouse spinal cord (lane 2), mouse testis (lane 3), mouse colon (lane 4) and human thyroid tumour (lane 5) samples were resolved on a 10% SDS PAGE gel and blots probed with NBP2-75898 at 1.5 ug/ml before being detected by a secondary antibody. The expected band size (269 kDa) is seen in the human-derived samples, as well as a band corresponding to dimers.")
![Western Blot: IFN-gamma Antibody (D9D10) [NBP2-81044] - Western Blot using anti-IFN gamma antibody (D9D10) [NBP2-81044]. Human thymus lysate (35ug protein in RIPA buffer) was resolved on a 15% SDS PAGE gel and blots probed with the rabbit IgG-chimeric version of D9D10 [NBP2-81044] at 0.1 ug/ml before detection using an anti-rabbit secondary antibody. Protein was detected by chemiluminescence. The expected unmodified running size for IFN gamma is 19.3kDa, though the form shown here is likely glycosylated. NBP2-81044 successfully detected IFN gamma in human thymus samples.](http://images.novusbio.com/fullsize/IFN-gamma-Antibody-D9D10-Western-Blot-NBP2-81044-img0001.jpg "Western Blot: IFN-gamma Antibody (D9D10) [NBP2-81044] - Western Blot using anti-IFN gamma antibody (D9D10) [NBP2-81044]. Human thymus lysate (35ug protein in RIPA buffer) was resolved on a 15% SDS PAGE gel and blots probed with the rabbit IgG-chimeric version of D9D10 [NBP2-81044] at 0.1 ug/ml before detection using an anti-rabbit secondary antibody. Protein was detected by chemiluminescence. The expected unmodified running size for IFN gamma is 19.3kDa, though the form shown here is likely glycosylated. NBP2-81044 successfully detected IFN gamma in human thymus samples.")
![Functional: Human IL1 alpha Protein [NBP2-35051]](http://images.novusbio.com/fullsize/Human-IL1-alpha-Protein-Functional-NBP2-35051-img0001.jpg "Functional: Human IL1 alpha Protein [NBP2-35051]")
![SDS-Page: Human IL-1 alpha/IL-1F1 Protein [NBP2-35051]](http://images.novusbio.com/fullsize/Human-IL-1-alpha-IL-1F1-Protein-SDS-Page-NBP2-35051-img0002.jpg)